Latest / Community Health Media
Dr. Gregory Vidal, Dr. Pooja Advani, & Dr. Tari King - T-DXd in Early HER2+ Breast Cancer
How will DESTINY-Breast11 and DESTINY-Breast05 change the treatment of early-stage HER2-positive breast cancer?
Dr. Gregory Vidal, Dr. Pooja Advani, and Dr. Tari King discuss the landmark approvals of trastuzumab deruxtecan (T-DXd) and what they mean for medical oncologists and surgeons treating HER2-positive breast cancer. The conversation explores the impressive pathologic complete response rates seen in DESTINY-Breast11, the role of T-DXd in the neoadjuvant and adjuvant settings, surgical implications of higher response rates, and how clinicians can personalize treatment decisions for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.